Adaptive Biotechnologies stock tumbles after first earnings report since IPO

Health, Fitness & Food

Chad Robins, CEO of Adaptive Biotechnologies.

Anjali Sundaram | CNBC

Adaptive Biotechnologies shares fell by more than 7% in after-hours trading Tuesday after the biotech company posted a wider-than-expected loss in its first earnings report since going public.

The company posted a loss of $1.23 a share on revenue of $22.1 million. Wall Street analysts were expecting a loss of 14 cents per share on revenue of $19.3 million.

“We are making important progress across on key catalysts that will enable near-term product applications across our life sciences research, clinical diagnostics, and drug discovery businesses, unlocking one of the largest global addressable markets in healthcare,” Adaptive Biotechnologies CEO Chad Robins said in a statement.

Adaptive, which is developing what it calls an “immune medicine platform” to treat various diseases, went public on the Nasdaq on June 27. Adaptive Biotechnologies closed up more than 100% at $40.30 a share on its first trading day, making it at the time in the top five IPO debuts of the year.

Its stock closed at $43.08 a share Tuesday, up by about 6.9% since its IPO.

Advertisements

Products You May Like

Articles You May Like

Common antidepressant may ease anxiety more quickly than depression
Pelosi to Cramer: There’s no need to reinvent health care — just improve Obamacare
Can exercise slow down Alzheimer’s?
Beta-blockers for anxiety: What to know
Iron-rich foods may cancel out tomatoes’ anticancer benefits

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.